Increasing the success rate for Alzheimer's disease drug discovery and development - PubMed (original) (raw)

Editorial

Increasing the success rate for Alzheimer's disease drug discovery and development

Robert E Becker et al. Expert Opin Drug Discov. 2012 Apr.

Abstract

This paper responds to the fact that over 200 Alzheimer's disease (AD) drug candidates have failed to date and draws on searches of the literature for studies of error effects in drug developments and the authors' published works. In the same period, basic knowledge of AD pathology has greatly expanded providing both potential therapeutic targets and rationales for modifications in strategies for testing AD drug candidates. Current opinion generally holds that AD drug candidates have failed because they address pathology that is already too advanced. Less attention is paid to numerous reported methodological weaknesses capable of biasing AD clinical trials and drug developments and thus invalidating conclusions to be reached about the drugs being tested. The costs of quality controls possibly needed to better insure validity in AD drug developments raises concerns that progress toward success in AD drug development may be hindered by the costs of intervening against current methodological barriers to the successful completions of AD drug developments.

© 2012 Informa UK, Ltd.

PubMed Disclaimer

References

    1. Lindner MD, McArthur RA, Deadwyler SA, Hampson RE, Tariot PN. Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer’s Disease. In: McArthur RA, Borsini F, editors. Animal and Translational Models for CNS Drug Discovery: Neurologic Disorders. San Diego: Academic Press; 2008. pp. 93–157.
    1. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubios B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix HB, Grundman M, Schneider LS, Schlindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vallas B. Report of the task force on designing clinical trials in early (preclinical) dementia. Neurology. 2011;76:280–286. - PMC - PubMed
    1. Paul SM, Mytelka DS, Dunwiddle CT, Persinger CC, Numos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews: Drug Discovery. 2010;5:203–214. - PubMed
    1. Klein DF. The loss of serendipity in psychopharmacology. JAMA. 2008;299:1063–1065. - PubMed
    1. Lansbury PT. Back to the future: the ‘old fashioned’ way to new medications for neurodegenerations. Nature Reviews: Neuroscience. doi: 10.1038/nrn1435. - DOI

Publication types

MeSH terms

LinkOut - more resources